 Melanie Gleason
Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| School Health Services | 8 | 2018 | 206 | 1.200 |
Why?
| | Asthma | 19 | 2022 | 2042 | 1.070 |
Why?
| | Health Personnel | 2 | 2017 | 574 | 0.470 |
Why?
| | School Nursing | 3 | 2018 | 24 | 0.410 |
Why?
| | Anti-Asthmatic Agents | 6 | 2017 | 350 | 0.340 |
Why?
| | Respiratory Sounds | 1 | 2022 | 111 | 0.190 |
Why?
| | Child | 19 | 2022 | 18362 | 0.170 |
Why?
| | Schools | 4 | 2022 | 400 | 0.160 |
Why?
| | Program Development | 2 | 2018 | 345 | 0.160 |
Why?
| | Population | 1 | 2018 | 28 | 0.160 |
Why?
| | Self Care | 2 | 2016 | 350 | 0.140 |
Why?
| | Disease Management | 2 | 2018 | 563 | 0.130 |
Why?
| | Competency-Based Education | 1 | 2016 | 66 | 0.130 |
Why?
| | Urban Population | 1 | 2018 | 402 | 0.130 |
Why?
| | Nurse's Role | 1 | 2016 | 106 | 0.130 |
Why?
| | Prednisone | 2 | 2015 | 231 | 0.120 |
Why?
| | Evidence-Based Practice | 1 | 2016 | 185 | 0.110 |
Why?
| | Program Evaluation | 1 | 2018 | 824 | 0.110 |
Why?
| | Child, Preschool | 9 | 2022 | 9083 | 0.110 |
Why?
| | Virus Diseases | 1 | 2015 | 196 | 0.110 |
Why?
| | Healthcare Disparities | 1 | 2018 | 480 | 0.110 |
Why?
| | Communication | 1 | 2017 | 747 | 0.100 |
Why?
| | Adolescent | 12 | 2022 | 17826 | 0.100 |
Why?
| | Practice Guidelines as Topic | 2 | 2016 | 1400 | 0.100 |
Why?
| | Spirometry | 3 | 2022 | 225 | 0.090 |
Why?
| | Nitric Oxide | 1 | 2015 | 827 | 0.090 |
Why?
| | Health Promotion | 1 | 2016 | 686 | 0.090 |
Why?
| | Parents | 1 | 2017 | 1191 | 0.090 |
Why?
| | Colorado | 5 | 2018 | 4089 | 0.080 |
Why?
| | Immunoglobulin E | 1 | 2010 | 317 | 0.080 |
Why?
| | Leukocytes, Mononuclear | 1 | 2012 | 496 | 0.080 |
Why?
| | Health Services Accessibility | 2 | 2018 | 765 | 0.080 |
Why?
| | Humans | 21 | 2022 | 114925 | 0.080 |
Why?
| | Adrenal Cortex Hormones | 1 | 2012 | 499 | 0.080 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2008 | 82 | 0.070 |
Why?
| | Aminopyridines | 1 | 2008 | 81 | 0.070 |
Why?
| | Benzamides | 1 | 2008 | 169 | 0.070 |
Why?
| | Dermatitis, Atopic | 1 | 2010 | 307 | 0.070 |
Why?
| | Food Hypersensitivity | 1 | 2010 | 254 | 0.070 |
Why?
| | Acetates | 1 | 2006 | 95 | 0.060 |
Why?
| | Quinolines | 1 | 2006 | 129 | 0.060 |
Why?
| | Male | 14 | 2018 | 55655 | 0.060 |
Why?
| | Female | 14 | 2018 | 59571 | 0.060 |
Why?
| | Drug Labeling | 1 | 2003 | 42 | 0.060 |
Why?
| | Anti-Allergic Agents | 1 | 2003 | 41 | 0.050 |
Why?
| | Patient Dropouts | 1 | 2003 | 66 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2003 | 172 | 0.050 |
Why?
| | Methacholine Chloride | 1 | 2022 | 47 | 0.050 |
Why?
| | Bronchial Provocation Tests | 1 | 2022 | 53 | 0.050 |
Why?
| | Forced Expiratory Volume | 3 | 2015 | 476 | 0.050 |
Why?
| | Patient Compliance | 1 | 2003 | 526 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2003 | 934 | 0.040 |
Why?
| | Connecticut | 1 | 2018 | 21 | 0.040 |
Why?
| | Case Management | 1 | 2018 | 62 | 0.040 |
Why?
| | Absenteeism | 1 | 2018 | 40 | 0.040 |
Why?
| | Respiratory Function Tests | 2 | 2012 | 524 | 0.040 |
Why?
| | Cyclopropanes | 2 | 2008 | 81 | 0.040 |
Why?
| | Nursing Education Research | 1 | 2016 | 31 | 0.030 |
Why?
| | Community Health Services | 1 | 2018 | 212 | 0.030 |
Why?
| | Research Design | 1 | 2022 | 932 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2005 | 2326 | 0.030 |
Why?
| | Organizational Case Studies | 1 | 2016 | 69 | 0.030 |
Why?
| | Focus Groups | 1 | 2017 | 385 | 0.030 |
Why?
| | Airway Resistance | 2 | 2006 | 33 | 0.030 |
Why?
| | Plethysmography | 2 | 2006 | 104 | 0.030 |
Why?
| | Patient Education as Topic | 2 | 2014 | 678 | 0.030 |
Why?
| | Exhalation | 1 | 2015 | 35 | 0.030 |
Why?
| | Breath Tests | 1 | 2015 | 82 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 834 | 0.030 |
Why?
| | Family | 1 | 2018 | 590 | 0.030 |
Why?
| | Drug Resistance | 2 | 2012 | 158 | 0.030 |
Why?
| | Acute Disease | 1 | 2015 | 915 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 995 | 0.030 |
Why?
| | Dual Specificity Phosphatase 1 | 1 | 2012 | 28 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2015 | 451 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2012 | 238 | 0.020 |
Why?
| | Receptors, Glucocorticoid | 1 | 2012 | 131 | 0.020 |
Why?
| | Double-Blind Method | 2 | 2006 | 1663 | 0.020 |
Why?
| | Immunoassay | 1 | 2010 | 95 | 0.020 |
Why?
| | Clinical Competence | 1 | 2016 | 901 | 0.020 |
Why?
| | Students | 1 | 2014 | 499 | 0.020 |
Why?
| | Dexamethasone | 1 | 2012 | 317 | 0.020 |
Why?
| | Food | 1 | 2010 | 160 | 0.020 |
Why?
| | Glucocorticoids | 1 | 1992 | 534 | 0.020 |
Why?
| | Half-Life | 1 | 2008 | 141 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2008 | 1856 | 0.020 |
Why?
| | Area Under Curve | 1 | 2008 | 275 | 0.020 |
Why?
| | Insurance, Health | 1 | 2009 | 244 | 0.020 |
Why?
| | Allergens | 1 | 2010 | 417 | 0.020 |
Why?
| | United States | 2 | 2018 | 12209 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2008 | 441 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2008 | 474 | 0.020 |
Why?
| | Lung Volume Measurements | 1 | 2006 | 45 | 0.020 |
Why?
| | Oscillometry | 1 | 2006 | 33 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2008 | 413 | 0.020 |
Why?
| | Sulfides | 1 | 2006 | 94 | 0.020 |
Why?
| | Electrocardiography | 1 | 2008 | 562 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 4406 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2012 | 2199 | 0.010 |
Why?
| | Infant | 2 | 2010 | 7936 | 0.010 |
Why?
| | Adult | 2 | 2018 | 30604 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2012 | 3897 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2012 | 1749 | 0.010 |
Why?
| | Prospective Studies | 1 | 2015 | 6218 | 0.010 |
Why?
| | Prognosis | 1 | 2012 | 3344 | 0.010 |
Why?
| | Airway Obstruction | 1 | 2006 | 168 | 0.010 |
Why?
| | Nedocromil | 1 | 2003 | 32 | 0.010 |
Why?
| | Budesonide | 1 | 2003 | 87 | 0.010 |
Why?
| | Social Class | 1 | 2003 | 204 | 0.010 |
Why?
| | Social Behavior | 1 | 2003 | 267 | 0.010 |
Why?
| | Hypersensitivity | 1 | 2003 | 256 | 0.010 |
Why?
| | Social Support | 1 | 2003 | 528 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2003 | 2382 | 0.010 |
Why?
| | Cognition | 1 | 2003 | 981 | 0.010 |
Why?
| | Young Adult | 1 | 2010 | 10476 | 0.010 |
Why?
| | Inflammation | 1 | 2005 | 2485 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2010 | 12543 | 0.010 |
Why?
| | Theophylline | 1 | 1992 | 60 | 0.010 |
Why?
| | Albuterol | 1 | 1992 | 103 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 1992 | 642 | 0.010 |
Why?
|
|
Gleason's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|